Effect of goserelin combined with recombinant human growth hormone on growth rate,uterine and ovarian volume,and bone metabolism in patients with central precocious puberty
Objective To investigate the effect of goserelin combined with recombinant human growth hormone(rhGH)on growth rate,uterine and ovarian volumes,and bone metabolism in patients with central precocious puberty(CPP).Methods A total of 84 CPP girls admitted to Zunhua People's Hospital from May 2020 to April 2022 were selected as study objects and randomly divided into observation group(n=42)and control group(n=42).The control group was treated with subcutaneous injection of goserelin,while the observation group was treated with rhGH in addition to the basis of control group.The growth rate,bone age and predictive adult height were measured before and after treatment.The volume of uterus and ovary in the two groups was observed and calculated under B-ultrasound.The levels of procollagen type Ⅰ N-propeptide(PINP),β-C-terminal telopeptide of type Ⅰ collagen(β-CTX)and N-terminal mid-fragment of osteocalcin(N-MID)of osteocalcin were detected by electrochemiluminescence immunoassay.The levels of follicle-stimulating hormone(FSH),estradiol(E2)and luteinizing hormone(LH)were detected by radioimmunoassay.Results There were no significant differences in the levels of height,predicted adult height,growth rate,bone age,uterine and ovarian volume,PINP,β-CTX,N-MID,E2,FSH and LH of child patients between the two groups before treatment(P＞0.05).After treatment,the height,predicted adult height and growth rate of the two groups were higher than before treatment.The height,predicted adult height and growth rate of observation group after treatment were higher than those of control group(t=2.812,2.159,2.049,P＜0.05).After treatment,the uterine and ovarian volumes of the two groups were smaller than before treatment,and those in the observation group were smaller than the control group(t=5.014,3.492,P＜0.05).After treatment,the levels of PINP,N-MID,E2,FSH and LH of the two groups were smaller than before treatment,and those in observation group were lower than control group(t=3.503,2.230,3.694,3.158,2.458,P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P＞0.05).Conclusions Goserelin combined with rhGH can slow down the development of secondary sexual characteristics in child patients with CPP,regulate bone metabolism and sex hormone levels.
Central precocious pubertyGoserelinRecombinant human growth hormoneGrowth rateBone metabolism
万方数据
维普
